The purpose of the report is to illustrate the state of the market of Antibody Drug Conjugate, to present actual information about the volumes of production, exports, imports, consumption and the state of the market, the changes that took place in 2017, and also, to build a forecast for the growth of the industry in the medium term until 2026.
Browse here for full report with Toc: https://www.credenceresearch.com/report/antibody-drug-conjugate-market
Antibody Drug Conjugates are monoclonal antibodies that are attached to biologically active drugs such as chemotherapeutic drugs, radioactive isotopes, cytokines or cytotoxins via chemical linkers with liable bonds. They combine the unique targeting property of monoclonal antibodies with the cancer cell killing ability of cytotoxic drugs. These allow discrimination between healthy and diseased tissues. Currently marketed drugs suffers from various stipulations like low potency, lack of specificity and adverse effects. This has forced the pharmaceutical and research companies to develop therapeutics that can overcome these barriers. Commercializing antibody drug conjugates have overcome these scenarios and improve the medical conditions. The currently marketed antibody drug conjugate drugs are Adcetris (Seattle Genetics) and Kadcyla (Genentech/Roche) followed by several Antibody Drug Conjugates (ADCs) in pipeline showcase the potential for innovations in this market.
The companies include Immunomedics, Spirogen, Pfizer, Roche/Genentech, Oxford BioTherapeutics, and Others.
Why was the report written?
This report is the result of an extensive survey drawn from Credence Research’s exclusive panel of leading global market industry executives; it provides data and analysis on buyer investment, acquisition, and developments within the global market research. It includes key topics such as global Antibody Drug Conjugate buyer expenditure and procurement behaviors and strategies and recognizes the threats and possibilities within the industry, economic outlook trends, and business confidence within global industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviors, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, Credence Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value chain of the global industry.
What is the current market landscape and what is changing?
Executives from the global industry anticipate an increase in levels of consolidation, with 55% of respondents projecting an increase in merger and acquisition (M&A) activities in 2017.
The report on the market of Antibody Drug Conjugate contains:
Analysis and forecast of Antibody Drug Conjugate market dynamics;
Analysis of domestic production, market shares of the main market players;
Analysis of exports and imports;
Analysis of factors, leading the development of the Antibody Drug Conjugate market;
Assessment and forecast of Antibody Drug Conjugate market development;
Financial and business profiles of the leading companies in the Antibody Drug Conjugate industry.
Also you can request us for sample in PDF with depth details and graph: https://www.credenceresearch.com/sample-request/58379
– Up to date working Antibody Drug Conjugate data by major regions in the world, the forecast of planned capacity additions by 2026
– The annual breakdown of capital expenditure spending on proposed Antibody Drug Conjugate for the period 2018 to 2026
– Planned Antibody Drug Conjugate additions and capital expenditure spending by key countries and companies across the world
– Planned capital expenditure spending on new Antibody Drug Conjugate projects by region, key countries, and companies
– Details of major planned Antibody Drug Conjugate projects in the world up to 2026
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Credence Research Inc.
105 N 1st ST #429
Toll Free (US/CANADA): +1-800-361-8290